Stockscreener 앱 받기
7.565
1.24%
-0.115
전일 마감가:
$7.68
열려 있는:
$7.4
하루 거래량:
951.81K
Relative Volume:
1.21
시가총액:
$564.82M
수익:
-
순이익/손실:
$-27.03M
주가수익비율:
-13.51
EPS:
-0.56
순현금흐름:
$-23.97M
1주 성능:
-0.07%
1개월 성능:
+5.49%
6개월 성능:
+109.53%
1년 성능:
-15.91%
1일 변동 폭
$7.33
$7.66
1주일 범위
$7.33
$8.44
52주 변동 폭
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
863 MITTEN ROAD, BURLINGAME, CA
CRVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
7.5801 | 572.27M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.04 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
627.25 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.36 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
830.00 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.91 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsEarnings Beat & Accurate Entry and Exit Point Alerts - newser.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikesTake Profit & Risk Controlled Stock Pick Alerts - newser.com
How to build a dashboard for Corvus Pharmaceuticals Inc. stockExit Point & Fast Gaining Stock Strategy Reports - newser.com
Corvus to present final data on T cell lymphoma drug at ASH meeting - Investing.com
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition - The Manila Times
Corvus Pharma (NASDAQ: CRVS) to present soquelitinib 1/1b T‑cell lymphoma data at ASH - Stock Titan
Corvus Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Real time social sentiment graph for Corvus Pharmaceuticals Inc.2025 Performance Recap & Entry Point Strategy Guides - newser.com
What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackRate Hike & Safe Capital Growth Trade Ideas - newser.com
What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Trend Report & Technical Entry and Exit Tips - newser.com
Why Corvus Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a bottoming base2025 Big Picture & Verified Entry Point Signals - newser.com
What momentum indicators show for Corvus Pharmaceuticals Inc. stockJuly 2025 Volume & High Accuracy Swing Entry Alerts - newser.com
Should you wait for a breakout in Corvus Pharmaceuticals Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025July 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Combining price and volume data for Corvus Pharmaceuticals Inc.Quarterly Earnings Report & Fast Exit and Entry Trade Guides - newser.com
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth - Sahm
Corvus Pharmaceuticals Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Tuesday - MarketBeat
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
Corvus Pharmaceuticals, Inc. (CRVS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Corvus Pharmaceuticals, Inc. (CRVS) Analyst insights, Price targets and Recommendations - Yahoo! Finance Singapore
Corvus Pharmaceuticals Inc. stock momentum explained2025 Analyst Calls & Precise Buy Zone Tips - newser.com
ETFs Investing in Corvus Pharmaceuticals, Inc. Stocks - TradingView
Will Corvus Pharmaceuticals Inc. stock benefit from green energy trendsEarnings Risk Report & Growth Focused Entry Reports - Fundação Cultural do Pará
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times
Corvus Pharma (NASDAQ: CRVS) to host Nov. 4 webcast for financial results update - Stock Titan
How Corvus Pharmaceuticals Inc. stock reacts to Fed rate cuts - fcp.pa.gov.br
Will Corvus Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Earnings Recap & AI Based Trade Execution Alerts - fcp.pa.gov.br
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.Analyst Downgrade & Safe Swing Trade Setup Alerts - newser.com
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.56%
자본화:
|
볼륨(24시간):